Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Takeda provides update on Novavax, Moderna COVID-19 vaccine candidates in Japan » 05:29
02/24/21
02/24
05:29
02/24/21
05:29
TAK

Takeda Pharmaceutical

$17.15 /

-0.15 (-0.87%)

, NVAX

Novavax

$243.21 /

-2.2 (-0.90%)

, MRNA

Moderna

$150.02 /

-9.27 (-5.82%)

Takeda Pharmaceutical…

Takeda Pharmaceutical (TAK) announced that the first subject was dosed in its Phase 1/2 immunogenicity and safety study of Novavax's (NVAX) COVID-19 vaccine candidate in Japan. Earlier this month, Takeda completed enrollment in the company's Phase 1/2 immunogenicity and safety study of Moderna's (MRNA) COVID-19 vaccine candidate in Japan. Takeda previously announced its commitment to providing access to COVID-19 vaccines in Japan through partnerships with Novavax and Moderna. Takeda will receive a manufacturing technology transfer from Novavax and will be responsible for the development and commercialization based on manufacturing capacity of over 250M doses of TAK-019. The company will also import and distribute 50M doses of TAK-919 as part of a joint partnership with Moderna and the Government of Japan's Ministry of Health Labour and Welfare, or MHLW. Results from the TAK-919 study are expected in the first half of 2021 and results from the TAK-019 study in the second half of 2021. Once available, the study results will be submitted to the Japan Pharmaceuticals and Medical Devices Agency, or PMDA, as part of the NDA filing process. Pending regulatory approval, Takeda intends to start distributing TAK-919 in the first half of 2021 and aims to start distributing TAK-019 in late 2021.

ShowHide Related Items >><<
TAK Takeda Pharmaceutical
$17.15 /

-0.15 (-0.87%)

NVAX Novavax
$243.21 /

-2.2 (-0.90%)

MRNA Moderna
$150.02 /

-9.27 (-5.82%)

TAK Takeda Pharmaceutical
$17.15 /

-0.15 (-0.87%)

01/29/21 Morgan Stanley
Morgan Stanley downgrades Jazz to Equal Weight ahead of competitor readout
12/29/20 Needham
Needham names Phathom Pharmaceuticals Top Pick for 2021
12/15/20 Needham
Phathom Pharmaceuticals price target raised to $55 from $45 at Needham
06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
NVAX Novavax
$243.21 /

-2.2 (-0.90%)

02/23/21 B. Riley Securities
B. Riley remains 'aggressive' buyer of Novavax after updated FDA guidance
02/22/21 Cantor Fitzgerald
Cantor says PREVENT-19 gives Novavax potential for differentiated analyses
02/22/21 B. Riley Securities
B. Riley reiterates Buy rating on Novavax as PREVENT-19 enrollment wraps up
02/18/21 B. Riley Securities
Novavax price target raised to $397 from $334 at B. Riley Securities
MRNA Moderna
$150.02 /

-9.27 (-5.82%)

02/18/21 Jefferies
Moderna price target raised to $180 from $150 at Jefferies
02/18/21 Morgan Stanley
Moderna price target raised to $215 from $150 at Morgan Stanley
02/17/21 Piper Sandler
Moderna price target raised to $208 from $170 at Piper Sandler
02/03/21 Piper Sandler
Moderna's vaccine approved in Singapore, says Piper Sandler
NVAX Novavax
$243.21 /

-2.2 (-0.90%)

MRNA Moderna
$150.02 /

-9.27 (-5.82%)

  • 19
    May
TAK Takeda Pharmaceutical
$17.15 /

-0.15 (-0.87%)

NVAX Novavax
$243.21 /

-2.2 (-0.90%)

MRNA Moderna
$150.02 /

-9.27 (-5.82%)

TAK Takeda Pharmaceutical
$17.15 /

-0.15 (-0.87%)

NVAX Novavax
$243.21 /

-2.2 (-0.90%)

MRNA Moderna
$150.02 /

-9.27 (-5.82%)

TAK Takeda Pharmaceutical
$17.15 /

-0.15 (-0.87%)

NVAX Novavax
$243.21 /

-2.2 (-0.90%)

MRNA Moderna
$150.02 /

-9.27 (-5.82%)

Over a week ago
Initiation
Phathom Pharmaceuticals initiated with an Outperform at BMO Capital » 06:11
02/17/21
02/17
06:11
02/17/21
06:11
PHAT

Phathom Pharmaceuticals

$42.86 /

-2.11 (-4.69%)

BMO Capital analyst Gary…

BMO Capital analyst Gary Nachman initiated coverage of Phathom Pharmaceuticals with an Outperform rating and $63 price target. The stock is an "exciting pure-play" in gastroenterology offering major catalysts this year that include the Vonoprazan Phase 3 data for H. Pylori Q2 and gastroesophageal reflux disorder in the second half of 2021, the analyst tells investors in a research note, adding that these could show meaningful improvement over standard-of-care.

ShowHide Related Items >><<
PHAT Phathom Pharmaceuticals
$42.86 /

-2.11 (-4.69%)

PHAT Phathom Pharmaceuticals
$42.86 /

-2.11 (-4.69%)

02/02/21 Guggenheim
Phathom Pharmaceuticals initiated with a Buy at Guggenheim
01/28/21
Fly Intel: Top five analyst initiations
01/28/21 JonesTrading
Phathom Pharmaceuticals initiated with a Buy at JonesTrading
12/29/20 Needham
Needham names Phathom Pharmaceuticals Top Pick for 2021
PHAT Phathom Pharmaceuticals
$42.86 /

-2.11 (-4.69%)

  • 17
    Dec
Hot Stocks
Takeda Pharmaceutical's maribavir Phase 3 clinical trial met primary endpoint » 06:03
02/12/21
02/12
06:03
02/12/21
06:03
TAK

Takeda Pharmaceutical

$17.54 /

+0.01 (+0.06%)

Takeda Pharmaceutical…

Takeda Pharmaceutical announced new, late-breaking Phase 3 data from the TAK-620-303 (SOLSTICE) trial, for the investigational drug TAK-620 (maribavir) which met its primary endpoint of superiority compared to conventional antiviral therapies, one or a combination of ganciclovir, valganciclovir, foscarnet or cidofovir in transplant recipients with refractory, with or without resistance, cytomegalovirus infection/disease. Overall, more than twice as many transplant recipients with R/R CMV infection/disease treated with maribavir achieved confirmed CMV viremia clearance at Study Week 8, the study's primary endpoint, as compared to 23.9% of those on conventional antiviral therapies. The study's key secondary endpoint was met by demonstrating maribavir's improvement over conventional therapies in clearance of CMV viremia and associated symptom control maintained through Study Week 16. Transplant recipients receiving maribavir exhibited lower incidence of treatment-related toxicities common with conventional antiviral therapies. Those receiving maribavir experienced lower rates of treatment-related neutropenia vs. valganciclovir/ganciclovir and acute kidney injury vs. foscarnet. Any treatment-emergent adverse events were 97.4 for maribavir and 91.4% for the conventional therapy group. TEAEs leading to study drug discontinuation were 13.2% in the maribavir group and 31.9% in the conventional therapy group. Two treatment-related serious TEAEs led to death.

ShowHide Related Items >><<
TAK Takeda Pharmaceutical
$17.54 /

+0.01 (+0.06%)

TAK Takeda Pharmaceutical
$17.54 /

+0.01 (+0.06%)

01/29/21 Morgan Stanley
Morgan Stanley downgrades Jazz to Equal Weight ahead of competitor readout
12/29/20 Needham
Needham names Phathom Pharmaceuticals Top Pick for 2021
12/15/20 Needham
Phathom Pharmaceuticals price target raised to $55 from $45 at Needham
06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
TAK Takeda Pharmaceutical
$17.54 /

+0.01 (+0.06%)

TAK Takeda Pharmaceutical
$17.54 /

+0.01 (+0.06%)

TAK Takeda Pharmaceutical
$17.54 /

+0.01 (+0.06%)

Conference/Events
Lysosomal Disease Network to hold a virtual symposium » 04:55
02/12/21
02/12
04:55
02/12/21
04:55
ABEO

Abeona Therapeutics

$3.36 /

+0.01 (+0.30%)

, AVRO

Avrobio

$16.85 /

+0.05 (+0.30%)

, BMRN

BioMarin

$86.80 /

+1.37 (+1.60%)

, DNLI

Denali Therapeutics

$69.32 /

-4.115 (-5.60%)

, FIXX

Homology Medicines

$13.75 /

-0.24 (-1.72%)

, FOLD

Amicus

$18.73 /

-0.86 (-4.39%)

, IDRSF

Idorsia

$0.00 /

+ (+0.00%)

, NVTA

Invitae

$51.13 /

-0.91 (-1.75%)

, ORPH

Orphazyme

$12.79 /

-0.01 (-0.08%)

, ORTX

Orchard Therapeutics

$8.20 /

-0.07 (-0.85%)

, PASG

Passage Bio

$21.44 /

+1.465 (+7.33%)

, PFE

Pfizer

$34.43 /

-0.31 (-0.89%)

, RARE

Ultragenyx

$162.86 /

-4.38 (-2.62%)

, SGTX

Sigilon Therapeutics

$39.79 /

+1.04 (+2.68%)

, SNY

Sanofi

$47.68 /

-0.375 (-0.78%)

, TAK

Takeda Pharmaceutical

$17.54 /

+0.01 (+0.06%)

, TVTX

Travere Therapeutics

$27.75 /

-1.23 (-4.24%)

17th Annual Virtual…

17th Annual Virtual WORLDSymposium 2021 will be held on February 8-12. Webcast Link

ShowHide Related Items >><<
TVTX Travere Therapeutics
$27.75 /

-1.23 (-4.24%)

TAK Takeda Pharmaceutical
$17.54 /

+0.01 (+0.06%)

SNY Sanofi
$47.68 /

-0.375 (-0.78%)

SGTX Sigilon Therapeutics
$39.79 /

+1.04 (+2.68%)

RARE Ultragenyx
$162.86 /

-4.38 (-2.62%)

PFE Pfizer
$34.43 /

-0.31 (-0.89%)

PASG Passage Bio
$21.44 /

+1.465 (+7.33%)

ORTX Orchard Therapeutics
$8.20 /

-0.07 (-0.85%)

ORPH Orphazyme
$12.79 /

-0.01 (-0.08%)

NVTA Invitae
$51.13 /

-0.91 (-1.75%)

FOLD Amicus
$18.73 /

-0.86 (-4.39%)

FIXX Homology Medicines
$13.75 /

-0.24 (-1.72%)

DNLI Denali Therapeutics
$69.32 /

-4.115 (-5.60%)

BMRN BioMarin
$86.80 /

+1.37 (+1.60%)

AVRO Avrobio
$16.85 /

+0.05 (+0.30%)

ABEO Abeona Therapeutics
$3.36 /

+0.01 (+0.30%)

ABEO Abeona Therapeutics
$3.36 /

+0.01 (+0.30%)

11/25/20 H.C. Wainwright
Abeona Therapeutics price target lowered to $8 from $11 at H.C. Wainwright
11/11/20 B. Riley Securities
Abeona Therapeutics price target raised to $3 from $2 at B. Riley Securities
11/10/20 Cantor Fitzgerald
Cantor upgrades Abeona to Overweight with shares trading near cash
11/10/20 Cantor Fitzgerald
Abeona Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
AVRO Avrobio
$16.85 /

+0.05 (+0.30%)

11/18/20 Mizuho
Avrobio price target raised to $43 from $35 at Mizuho
11/11/20 Berenberg
Biotechnology companies initiated at Berenberg
11/11/20 Berenberg
Avrobio initiated with a Buy at Berenberg
03/31/20 H.C. Wainwright
Avrobio downgraded to Neutral from Buy at H.C. Wainwright
BMRN BioMarin
$86.80 /

+1.37 (+1.60%)

01/29/21 Jefferies
Carvana, Walmart among 13 additions to Jefferies Franchise Picks list
01/11/21 Baird
BioMarin price target raised to $110 from $100 at Baird
12/21/20 Piper Sandler
BioMarin data today should ease approvability concerns, says Piper Sandler
12/17/20 JPMorgan
BioMarin remains 'highest conviction name' at JPMorgan
DNLI Denali Therapeutics
$69.32 /

-4.115 (-5.60%)

02/10/21
Fly Intel: Top five analyst upgrades
02/10/21 Cantor Fitzgerald
Denali Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
11/11/20 JPMorgan
Denali Therapeutics price target raised to $65 from $45 at JPMorgan
11/11/20 H.C. Wainwright
Denali Therapeutics price target raised to $80 from $65 at H.C. Wainwright
FIXX Homology Medicines
$13.75 /

-0.24 (-1.72%)

12/14/20 H.C. Wainwright
Homology Medicines transferred with Buy, $30 target at H.C. Wainwright
11/08/20 Oppenheimer
Homology Medicines selloff unjustified in wake of clinical PoC, says Oppenheimer
08/11/20 Oppenheimer
Homology Medicines price target lowered to $27 from $32 at Oppenheimer
08/11/20 H.C. Wainwright
Homology Medicines price target lowered to $30 from $37 at H.C. Wainwright
FOLD Amicus
$18.73 /

-0.86 (-4.39%)

02/12/21 Cantor Fitzgerald
Amicus downgraded to Neutral from Overweight at Cantor Fitzgerald
02/12/21 JPMorgan
Amicus downgraded to Neutral from Overweight at JPMorgan
01/22/21 JPMorgan
Amicus remains top idea into 'meaningful catalyst' at JPMorgan
01/04/21 Cowen
Amicus could move 30%-40% on Pompe study data, says Cowen
IDRSF Idorsia
$0.00 /

+ (+0.00%)

02/10/21 Morgan Stanley
Idorsia price target lowered to CHF 32 from CHF 34 at Morgan Stanley
02/08/21 JPMorgan
Idorsia price target lowered to CHF 28 from CHF 31 at JPMorgan
10/29/20 Morgan Stanley
Idorsia price target lowered to CHF 34 from CHF 35 at Morgan Stanley
10/28/20 JPMorgan
Idorsia price target lowered to CHF 30 from CHF 34 at JPMorgan
NVTA Invitae
$51.13 /

-0.91 (-1.75%)

02/01/21 Oppenheimer
Invitae downgraded to Perform on valuation at Oppenheimer
02/01/21 Oppenheimer
Invitae downgraded to Perform from Outperform at Oppenheimer
11/06/20 Ladenburg
Invitae downgraded to Neutral on valuation at Ladenburg
11/06/20 Ladenburg
Invitae downgraded to Neutral from Buy at Ladenburg
ORPH Orphazyme
$12.79 /

-0.01 (-0.08%)

10/26/20 Guggenheim
Orphazyme initiated with a Buy at Guggenheim
10/26/20 BofA
Orphazyme initiated with a Buy at BofA
10/26/20 BofA
Orphazyme initiated with a Buy at BofA
ORTX Orchard Therapeutics
$8.20 /

-0.07 (-0.85%)

01/07/21 Cantor Fitzgerald
Orchard Therapeutics initiated with an Overweight at Cantor Fitzgerald
01/06/21 Cantor Fitzgerald
Orchard Therapeutics initiated with an Overweight at Cantor Fitzgerald
09/14/20 Oppenheimer
Orchard Therapeutics price target lowered to $16 from $26 at Oppenheimer
09/10/20 SMBC Nikko
Orchard Therapeutics initiated with an Outperform at SMBC Nikko
PASG Passage Bio
$21.44 /

+1.465 (+7.33%)

02/04/21
Fly Intel: Top five analyst initiations
02/04/21 Guggenheim
Passage Bio initiated with a Buy at Guggenheim
01/25/21 Citi
Citi upgrades Passage Bio to Buy after pullback and ahead of data
01/25/21 Citi
Passage Bio upgraded to Buy from Neutral at Citi
PFE Pfizer
$34.43 /

-0.31 (-0.89%)

02/10/21 KeyBanc
Maravai Lifesciences price target raised to $39 from $33 at KeyBanc
02/04/21 DZ Bank
Pfizer upgraded to Buy from Hold at DZ Bank
02/03/21 Mizuho
Pfizer price target lowered to $42 from $44 at Mizuho
02/01/21 SVB Leerink
Moderna price target raised to $80 from $69 at SVB Leerink
RARE Ultragenyx
$162.86 /

-4.38 (-2.62%)

02/11/21 Piper Sandler
Ultragenyx price target raised to $170 from $165 at Piper Sandler
01/25/21 Credit Suisse
Ultragenyx price target raised to $99 from $64 at Credit Suisse
01/11/21 Baird
Ultragenyx price target raised to $165 from $110 at Baird
01/11/21 Barclays
Ultragenyx price target raised to $176 from $121 at Barclays
SGTX Sigilon Therapeutics
$39.79 /

+1.04 (+2.68%)

12/29/20 Barclays
Sigilon Therapeutics initiated with an Overweight at Barclays
12/29/20 Morgan Stanley
Sigilon Therapeutics initiated with an Equal Weight at Morgan Stanley
12/29/20 Jefferies
Sigilon Therapeutics initiated with a Buy at Jefferies
SNY Sanofi
$47.68 /

-0.375 (-0.78%)

02/10/21 Morgan Stanley
Sanofi price target raised to EUR 104 from EUR 101 at Morgan Stanley
02/05/21 Piper Sandler
Piper reiterates Overweight on Kymera after Sanofi capital markets day
01/19/21 UBS
Sanofi price target lowered to EUR 99 from EUR 100 at UBS
01/15/21 Deutsche Bank
Sanofi initiated with a Sell at Deutsche Bank
TAK Takeda Pharmaceutical
$17.54 /

+0.01 (+0.06%)

01/29/21 Morgan Stanley
Morgan Stanley downgrades Jazz to Equal Weight ahead of competitor readout
12/29/20 Needham
Needham names Phathom Pharmaceuticals Top Pick for 2021
12/15/20 Needham
Phathom Pharmaceuticals price target raised to $55 from $45 at Needham
06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
TVTX Travere Therapeutics
$27.75 /

-1.23 (-4.24%)

02/03/21
Travere Therapeutics price target raised to $48 from $33 at BMO Capital
02/03/21 Canaccord
Travere Therapeutics price target raised to $51 from $28 at Canaccord
11/23/20 Evercore ISI
Travere Therapeutics initiated with an Outperform at Evercore ISI
TVTX Travere Therapeutics
$27.75 /

-1.23 (-4.24%)

SNY Sanofi
$47.68 /

-0.375 (-0.78%)

RARE Ultragenyx
$162.86 /

-4.38 (-2.62%)

PFE Pfizer
$34.43 /

-0.31 (-0.89%)

PASG Passage Bio
$21.44 /

+1.465 (+7.33%)

ORTX Orchard Therapeutics
$8.20 /

-0.07 (-0.85%)

NVTA Invitae
$51.13 /

-0.91 (-1.75%)

FOLD Amicus
$18.73 /

-0.86 (-4.39%)

FIXX Homology Medicines
$13.75 /

-0.24 (-1.72%)

DNLI Denali Therapeutics
$69.32 /

-4.115 (-5.60%)

BMRN BioMarin
$86.80 /

+1.37 (+1.60%)

AVRO Avrobio
$16.85 /

+0.05 (+0.30%)

ABEO Abeona Therapeutics
$3.36 /

+0.01 (+0.30%)

  • 12
    Feb
  • 22
    Jan
  • 22
    Jan
  • 04
    Dec
  • 20
    Nov
  • 29
    Oct
  • 29
    Sep
  • 02
    Apr
  • 28
    Feb
  • 13
    Feb
TAK Takeda Pharmaceutical
$17.54 /

+0.01 (+0.06%)

SNY Sanofi
$47.68 /

-0.375 (-0.78%)

PFE Pfizer
$34.43 /

-0.31 (-0.89%)

FOLD Amicus
$18.73 /

-0.86 (-4.39%)

BMRN BioMarin
$86.80 /

+1.37 (+1.60%)

TAK Takeda Pharmaceutical
$17.54 /

+0.01 (+0.06%)

SNY Sanofi
$47.68 /

-0.375 (-0.78%)

SGTX Sigilon Therapeutics
$39.79 /

+1.04 (+2.68%)

PFE Pfizer
$34.43 /

-0.31 (-0.89%)

PASG Passage Bio
$21.44 /

+1.465 (+7.33%)

ORPH Orphazyme
$12.79 /

-0.01 (-0.08%)

NVTA Invitae
$51.13 /

-0.91 (-1.75%)

FOLD Amicus
$18.73 /

-0.86 (-4.39%)

DNLI Denali Therapeutics
$69.32 /

-4.115 (-5.60%)

BMRN BioMarin
$86.80 /

+1.37 (+1.60%)

AVRO Avrobio
$16.85 /

+0.05 (+0.30%)

TVTX Travere Therapeutics
$27.75 /

-1.23 (-4.24%)

TAK Takeda Pharmaceutical
$17.54 /

+0.01 (+0.06%)

PFE Pfizer
$34.43 /

-0.31 (-0.89%)

PASG Passage Bio
$21.44 /

+1.465 (+7.33%)

NVTA Invitae
$51.13 /

-0.91 (-1.75%)

FOLD Amicus
$18.73 /

-0.86 (-4.39%)

BMRN BioMarin
$86.80 /

+1.37 (+1.60%)

Conference/Events
Lysosomal Disease Network to hold a virtual symposium » 04:55
02/11/21
02/11
04:55
02/11/21
04:55
ABEO

Abeona Therapeutics

$3.35 /

+0.025 (+0.75%)

, AVRO

Avrobio

$16.80 /

-0.88 (-4.98%)

, BMRN

BioMarin

$85.43 /

-0.31 (-0.36%)

, DNLI

Denali Therapeutics

$73.36 /

+0.38 (+0.52%)

, FIXX

Homology Medicines

$14.00 /

-0.36 (-2.51%)

, FOLD

Amicus

$19.59 /

+0.41 (+2.14%)

, IDRSF

Idorsia

$0.00 /

+ (+0.00%)

, NVTA

Invitae

$51.98 /

-0.57 (-1.08%)

, ORPH

Orphazyme

$12.79 /

-0.28 (-2.14%)

, ORTX

Orchard Therapeutics

$8.27 /

-0.09 (-1.08%)

, PASG

Passage Bio

$19.87 /

-0.22 (-1.10%)

, PFE

Pfizer

$34.74 /

-0.22 (-0.63%)

, RARE

Ultragenyx

$167.17 /

-0.19 (-0.11%)

, SGTX

Sigilon Therapeutics

$38.75 /

+0.48 (+1.25%)

, SNY

Sanofi

$48.06 /

-0.815 (-1.67%)

, TAK

Takeda Pharmaceutical

$17.53 /

-0.195 (-1.10%)

, TVTX

Travere Therapeutics

$28.98 /

-0.93 (-3.11%)

17th Annual Virtual…

17th Annual Virtual WORLDSymposium 2021 will be held on February 8-12. Webcast Link

ShowHide Related Items >><<
TVTX Travere Therapeutics
$28.98 /

-0.93 (-3.11%)

TAK Takeda Pharmaceutical
$17.53 /

-0.195 (-1.10%)

SNY Sanofi
$48.06 /

-0.815 (-1.67%)

SGTX Sigilon Therapeutics
$38.75 /

+0.48 (+1.25%)

RARE Ultragenyx
$167.17 /

-0.19 (-0.11%)

PFE Pfizer
$34.74 /

-0.22 (-0.63%)

PASG Passage Bio
$19.87 /

-0.22 (-1.10%)

ORTX Orchard Therapeutics
$8.27 /

-0.09 (-1.08%)

ORPH Orphazyme
$12.79 /

-0.28 (-2.14%)

NVTA Invitae
$51.98 /

-0.57 (-1.08%)

FOLD Amicus
$19.59 /

+0.41 (+2.14%)

FIXX Homology Medicines
$14.00 /

-0.36 (-2.51%)

DNLI Denali Therapeutics
$73.36 /

+0.38 (+0.52%)

BMRN BioMarin
$85.43 /

-0.31 (-0.36%)

AVRO Avrobio
$16.80 /

-0.88 (-4.98%)

ABEO Abeona Therapeutics
$3.35 /

+0.025 (+0.75%)

ABEO Abeona Therapeutics
$3.35 /

+0.025 (+0.75%)

11/25/20 H.C. Wainwright
Abeona Therapeutics price target lowered to $8 from $11 at H.C. Wainwright
11/11/20 B. Riley Securities
Abeona Therapeutics price target raised to $3 from $2 at B. Riley Securities
11/10/20 Cantor Fitzgerald
Cantor upgrades Abeona to Overweight with shares trading near cash
11/10/20 Cantor Fitzgerald
Abeona Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
AVRO Avrobio
$16.80 /

-0.88 (-4.98%)

11/18/20 Mizuho
Avrobio price target raised to $43 from $35 at Mizuho
11/11/20 Berenberg
Biotechnology companies initiated at Berenberg
11/11/20 Berenberg
Avrobio initiated with a Buy at Berenberg
03/31/20 H.C. Wainwright
Avrobio downgraded to Neutral from Buy at H.C. Wainwright
BMRN BioMarin
$85.43 /

-0.31 (-0.36%)

01/29/21 Jefferies
Carvana, Walmart among 13 additions to Jefferies Franchise Picks list
01/11/21 Baird
BioMarin price target raised to $110 from $100 at Baird
12/21/20 Piper Sandler
BioMarin data today should ease approvability concerns, says Piper Sandler
12/17/20 JPMorgan
BioMarin remains 'highest conviction name' at JPMorgan
DNLI Denali Therapeutics
$73.36 /

+0.38 (+0.52%)

02/10/21
Fly Intel: Top five analyst upgrades
02/10/21 Cantor Fitzgerald
Denali Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
11/11/20 JPMorgan
Denali Therapeutics price target raised to $65 from $45 at JPMorgan
11/11/20 H.C. Wainwright
Denali Therapeutics price target raised to $80 from $65 at H.C. Wainwright
FIXX Homology Medicines
$14.00 /

-0.36 (-2.51%)

12/14/20 H.C. Wainwright
Homology Medicines transferred with Buy, $30 target at H.C. Wainwright
11/08/20 Oppenheimer
Homology Medicines selloff unjustified in wake of clinical PoC, says Oppenheimer
08/11/20 Oppenheimer
Homology Medicines price target lowered to $27 from $32 at Oppenheimer
08/11/20 H.C. Wainwright
Homology Medicines price target lowered to $30 from $37 at H.C. Wainwright
FOLD Amicus
$19.59 /

+0.41 (+2.14%)

01/22/21 JPMorgan
Amicus remains top idea into 'meaningful catalyst' at JPMorgan
01/04/21 Cowen
Amicus could move 30%-40% on Pompe study data, says Cowen
12/28/20 Cantor Fitzgerald
Amicus assumed with an Overweight at Cantor Fitzgerald
12/14/20 JPMorgan
JPMorgan boosts Amicus target to $29, adds to Analyst Focus List
IDRSF Idorsia
$0.00 /

+ (+0.00%)

02/10/21 Morgan Stanley
Idorsia price target lowered to CHF 32 from CHF 34 at Morgan Stanley
02/08/21 JPMorgan
Idorsia price target lowered to CHF 28 from CHF 31 at JPMorgan
10/29/20 Morgan Stanley
Idorsia price target lowered to CHF 34 from CHF 35 at Morgan Stanley
10/28/20 JPMorgan
Idorsia price target lowered to CHF 30 from CHF 34 at JPMorgan
NVTA Invitae
$51.98 /

-0.57 (-1.08%)

02/01/21 Oppenheimer
Invitae downgraded to Perform on valuation at Oppenheimer
02/01/21 Oppenheimer
Invitae downgraded to Perform from Outperform at Oppenheimer
11/06/20 Ladenburg
Invitae downgraded to Neutral on valuation at Ladenburg
11/06/20 Ladenburg
Invitae downgraded to Neutral from Buy at Ladenburg
ORPH Orphazyme
$12.79 /

-0.28 (-2.14%)

10/26/20 Guggenheim
Orphazyme initiated with a Buy at Guggenheim
10/26/20 BofA
Orphazyme initiated with a Buy at BofA
10/26/20 BofA
Orphazyme initiated with a Buy at BofA
ORTX Orchard Therapeutics
$8.27 /

-0.09 (-1.08%)

01/07/21 Cantor Fitzgerald
Orchard Therapeutics initiated with an Overweight at Cantor Fitzgerald
01/06/21 Cantor Fitzgerald
Orchard Therapeutics initiated with an Overweight at Cantor Fitzgerald
09/14/20 Oppenheimer
Orchard Therapeutics price target lowered to $16 from $26 at Oppenheimer
09/10/20 SMBC Nikko
Orchard Therapeutics initiated with an Outperform at SMBC Nikko
PASG Passage Bio
$19.87 /

-0.22 (-1.10%)

02/04/21
Fly Intel: Top five analyst initiations
02/04/21 Guggenheim
Passage Bio initiated with a Buy at Guggenheim
01/25/21 Citi
Citi upgrades Passage Bio to Buy after pullback and ahead of data
01/25/21 Citi
Passage Bio upgraded to Buy from Neutral at Citi
PFE Pfizer
$34.74 /

-0.22 (-0.63%)

02/10/21 KeyBanc
Maravai Lifesciences price target raised to $39 from $33 at KeyBanc
02/04/21 DZ Bank
Pfizer upgraded to Buy from Hold at DZ Bank
02/03/21 Mizuho
Pfizer price target lowered to $42 from $44 at Mizuho
02/01/21 SVB Leerink
Moderna price target raised to $80 from $69 at SVB Leerink
RARE Ultragenyx
$167.17 /

-0.19 (-0.11%)

01/25/21 Credit Suisse
Ultragenyx price target raised to $99 from $64 at Credit Suisse
01/11/21 Baird
Ultragenyx price target raised to $165 from $110 at Baird
01/11/21 Barclays
Ultragenyx price target raised to $176 from $121 at Barclays
01/08/21 Piper Sandler
Ultragenyx price target raised to $165 from $108 at Piper Sandler
SGTX Sigilon Therapeutics
$38.75 /

+0.48 (+1.25%)

12/29/20 Barclays
Sigilon Therapeutics initiated with an Overweight at Barclays
12/29/20 Morgan Stanley
Sigilon Therapeutics initiated with an Equal Weight at Morgan Stanley
12/29/20 Jefferies
Sigilon Therapeutics initiated with a Buy at Jefferies
SNY Sanofi
$48.06 /

-0.815 (-1.67%)

02/10/21 Morgan Stanley
Sanofi price target raised to EUR 104 from EUR 101 at Morgan Stanley
02/05/21 Piper Sandler
Piper reiterates Overweight on Kymera after Sanofi capital markets day
01/19/21 UBS
Sanofi price target lowered to EUR 99 from EUR 100 at UBS
01/15/21 Deutsche Bank
Sanofi initiated with a Sell at Deutsche Bank
TAK Takeda Pharmaceutical
$17.53 /

-0.195 (-1.10%)

01/29/21 Morgan Stanley
Morgan Stanley downgrades Jazz to Equal Weight ahead of competitor readout
12/29/20 Needham
Needham names Phathom Pharmaceuticals Top Pick for 2021
12/15/20 Needham
Phathom Pharmaceuticals price target raised to $55 from $45 at Needham
06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
TVTX Travere Therapeutics
$28.98 /

-0.93 (-3.11%)

02/03/21
Travere Therapeutics price target raised to $48 from $33 at BMO Capital
02/03/21 Canaccord
Travere Therapeutics price target raised to $51 from $28 at Canaccord
11/23/20 Evercore ISI
Travere Therapeutics initiated with an Outperform at Evercore ISI
TVTX Travere Therapeutics
$28.98 /

-0.93 (-3.11%)

SNY Sanofi
$48.06 /

-0.815 (-1.67%)

RARE Ultragenyx
$167.17 /

-0.19 (-0.11%)

PFE Pfizer
$34.74 /

-0.22 (-0.63%)

PASG Passage Bio
$19.87 /

-0.22 (-1.10%)

ORTX Orchard Therapeutics
$8.27 /

-0.09 (-1.08%)

NVTA Invitae
$51.98 /

-0.57 (-1.08%)

FOLD Amicus
$19.59 /

+0.41 (+2.14%)

FIXX Homology Medicines
$14.00 /

-0.36 (-2.51%)

DNLI Denali Therapeutics
$73.36 /

+0.38 (+0.52%)

BMRN BioMarin
$85.43 /

-0.31 (-0.36%)

AVRO Avrobio
$16.80 /

-0.88 (-4.98%)

ABEO Abeona Therapeutics
$3.35 /

+0.025 (+0.75%)

  • 12
    Feb
  • 22
    Jan
  • 22
    Jan
  • 04
    Dec
  • 20
    Nov
  • 29
    Oct
  • 29
    Sep
  • 02
    Apr
  • 28
    Feb
  • 13
    Feb
TAK Takeda Pharmaceutical
$17.53 /

-0.195 (-1.10%)

SNY Sanofi
$48.06 /

-0.815 (-1.67%)

PFE Pfizer
$34.74 /

-0.22 (-0.63%)

FOLD Amicus
$19.59 /

+0.41 (+2.14%)

BMRN BioMarin
$85.43 /

-0.31 (-0.36%)

TAK Takeda Pharmaceutical
$17.53 /

-0.195 (-1.10%)

SNY Sanofi
$48.06 /

-0.815 (-1.67%)

SGTX Sigilon Therapeutics
$38.75 /

+0.48 (+1.25%)

PFE Pfizer
$34.74 /

-0.22 (-0.63%)

PASG Passage Bio
$19.87 /

-0.22 (-1.10%)

ORPH Orphazyme
$12.79 /

-0.28 (-2.14%)

NVTA Invitae
$51.98 /

-0.57 (-1.08%)

FOLD Amicus
$19.59 /

+0.41 (+2.14%)

DNLI Denali Therapeutics
$73.36 /

+0.38 (+0.52%)

BMRN BioMarin
$85.43 /

-0.31 (-0.36%)

AVRO Avrobio
$16.80 /

-0.88 (-4.98%)

TVTX Travere Therapeutics
$28.98 /

-0.93 (-3.11%)

TAK Takeda Pharmaceutical
$17.53 /

-0.195 (-1.10%)

PFE Pfizer
$34.74 /

-0.22 (-0.63%)

PASG Passage Bio
$19.87 /

-0.22 (-1.10%)

NVTA Invitae
$51.98 /

-0.57 (-1.08%)

FOLD Amicus
$19.59 /

+0.41 (+2.14%)

BMRN BioMarin
$85.43 /

-0.31 (-0.36%)

Hot Stocks
Takeda Pharmaceutical submits new drug application for darvadstrocel in Japan » 05:30
02/10/21
02/10
05:30
02/10/21
05:30
TAK

Takeda Pharmaceutical

$17.73 /

+0.315 (+1.81%)

Takeda Pharmaceutical…

Takeda Pharmaceutical announced that it has submitted an application to the Japanese Ministry of Health, Labour and Welfare to manufacture and market darvadstrocel for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn's disease, or CD. The application filing included data from two trials, the Japanese Study Darvadstrocel-3002 and the ADMIRE-CD trial, conducted in Europe and Israel. Study Darvadstrocel-3002 is a Phase 3, multicenter, open-label, uncontrolled study investigating the efficacy and safety of darvadstrocel for the treatment of complex perianal fistulas in 22 Japanese adult patients with non-active/mildly active luminal CD. Results from Study Darvadstrocel-3002 will be presented at a scientific meeting in the near future. ADMIRE-CD was a randomized, double-blind, controlled, Phase 3 trial investigating the efficacy and safety of darvadstrocel for the treatment of complex perianal fistulas in 212 adult patients with non-active/mildly active luminal CD.

ShowHide Related Items >><<
TAK Takeda Pharmaceutical
$17.73 /

+0.315 (+1.81%)

TAK Takeda Pharmaceutical
$17.73 /

+0.315 (+1.81%)

01/29/21 Morgan Stanley
Morgan Stanley downgrades Jazz to Equal Weight ahead of competitor readout
12/29/20 Needham
Needham names Phathom Pharmaceuticals Top Pick for 2021
12/15/20 Needham
Phathom Pharmaceuticals price target raised to $55 from $45 at Needham
06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
TAK Takeda Pharmaceutical
$17.73 /

+0.315 (+1.81%)

TAK Takeda Pharmaceutical
$17.73 /

+0.315 (+1.81%)

TAK Takeda Pharmaceutical
$17.73 /

+0.315 (+1.81%)

Conference/Events
Lysosomal Disease Network to hold a virtual symposium » 04:55
02/10/21
02/10
04:55
02/10/21
04:55
ABEO

Abeona Therapeutics

$3.32 /

-0.05 (-1.48%)

, AVRO

Avrobio

$17.68 /

-1.62 (-8.39%)

, BMRN

BioMarin

$85.63 /

-0.55 (-0.64%)

, DNLI

Denali Therapeutics

$72.98 /

-3.57 (-4.66%)

, FIXX

Homology Medicines

$14.38 /

-0.39 (-2.64%)

, FOLD

Amicus

$19.18 /

-0.7 (-3.52%)

, IDRSF

Idorsia

$0.00 /

+ (+0.00%)

, NVTA

Invitae

$52.55 /

+1.74 (+3.42%)

, ORPH

Orphazyme

$13.07 /

+ (+0.00%)

, ORTX

Orchard Therapeutics

$8.32 /

+1.055 (+14.52%)

, PASG

Passage Bio

$20.12 /

-0.57 (-2.75%)

, PFE

Pfizer

$34.96 /

+0.14 (+0.40%)

, RARE

Ultragenyx

$167.72 /

+1.9 (+1.15%)

, SGTX

Sigilon Therapeutics

$38.27 /

-0.4 (-1.03%)

, SNY

Sanofi

$48.87 /

+0.275 (+0.57%)

, TAK

Takeda Pharmaceutical

$17.73 /

+0.315 (+1.81%)

, TVTX

Travere Therapeutics

$29.91 /

-1.09 (-3.52%)

17th Annual Virtual…

17th Annual Virtual WORLDSymposium 2021 will be held on February 8-12. Webcast Link

ShowHide Related Items >><<
TVTX Travere Therapeutics
$29.91 /

-1.09 (-3.52%)

TAK Takeda Pharmaceutical
$17.73 /

+0.315 (+1.81%)

SNY Sanofi
$48.87 /

+0.275 (+0.57%)

SGTX Sigilon Therapeutics
$38.27 /

-0.4 (-1.03%)

RARE Ultragenyx
$167.72 /

+1.9 (+1.15%)

PFE Pfizer
$34.96 /

+0.14 (+0.40%)

PASG Passage Bio
$20.12 /

-0.57 (-2.75%)

ORTX Orchard Therapeutics
$8.32 /

+1.055 (+14.52%)

ORPH Orphazyme
$13.07 /

+ (+0.00%)

NVTA Invitae
$52.55 /

+1.74 (+3.42%)

FOLD Amicus
$19.18 /

-0.7 (-3.52%)

FIXX Homology Medicines
$14.38 /

-0.39 (-2.64%)

DNLI Denali Therapeutics
$72.98 /

-3.57 (-4.66%)

BMRN BioMarin
$85.63 /

-0.55 (-0.64%)

AVRO Avrobio
$17.68 /

-1.62 (-8.39%)

ABEO Abeona Therapeutics
$3.32 /

-0.05 (-1.48%)

ABEO Abeona Therapeutics
$3.32 /

-0.05 (-1.48%)

11/25/20 H.C. Wainwright
Abeona Therapeutics price target lowered to $8 from $11 at H.C. Wainwright
11/11/20 B. Riley Securities
Abeona Therapeutics price target raised to $3 from $2 at B. Riley Securities
11/10/20 Cantor Fitzgerald
Cantor upgrades Abeona to Overweight with shares trading near cash
11/10/20 Cantor Fitzgerald
Abeona Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
AVRO Avrobio
$17.68 /

-1.62 (-8.39%)

11/18/20 Mizuho
Avrobio price target raised to $43 from $35 at Mizuho
11/11/20 Berenberg
Biotechnology companies initiated at Berenberg
11/11/20 Berenberg
Avrobio initiated with a Buy at Berenberg
03/31/20 H.C. Wainwright
Avrobio downgraded to Neutral from Buy at H.C. Wainwright
BMRN BioMarin
$85.63 /

-0.55 (-0.64%)

01/29/21 Jefferies
Carvana, Walmart among 13 additions to Jefferies Franchise Picks list
01/11/21 Baird
BioMarin price target raised to $110 from $100 at Baird
12/21/20 Piper Sandler
BioMarin data today should ease approvability concerns, says Piper Sandler
12/17/20 JPMorgan
BioMarin remains 'highest conviction name' at JPMorgan
DNLI Denali Therapeutics
$72.98 /

-3.57 (-4.66%)

11/11/20 JPMorgan
Denali Therapeutics price target raised to $65 from $45 at JPMorgan
11/11/20 H.C. Wainwright
Denali Therapeutics price target raised to $80 from $65 at H.C. Wainwright
11/10/20 Goldman Sachs
Denali Therapeutics price target raised to $81 from $61 at Goldman Sachs
11/06/20 H.C. Wainwright
Denali Therapeutics price target raised to $65 from $45 at H.C. Wainwright
FIXX Homology Medicines
$14.38 /

-0.39 (-2.64%)

12/14/20 H.C. Wainwright
Homology Medicines transferred with Buy, $30 target at H.C. Wainwright
11/08/20 Oppenheimer
Homology Medicines selloff unjustified in wake of clinical PoC, says Oppenheimer
08/11/20 Oppenheimer
Homology Medicines price target lowered to $27 from $32 at Oppenheimer
08/11/20 H.C. Wainwright
Homology Medicines price target lowered to $30 from $37 at H.C. Wainwright
FOLD Amicus
$19.18 /

-0.7 (-3.52%)

01/22/21 JPMorgan
Amicus remains top idea into 'meaningful catalyst' at JPMorgan
01/04/21 Cowen
Amicus could move 30%-40% on Pompe study data, says Cowen
12/28/20 Cantor Fitzgerald
Amicus assumed with an Overweight at Cantor Fitzgerald
12/14/20 JPMorgan
JPMorgan boosts Amicus target to $29, adds to Analyst Focus List
IDRSF Idorsia
$0.00 /

+ (+0.00%)

02/08/21 JPMorgan
Idorsia price target lowered to CHF 28 from CHF 31 at JPMorgan
10/29/20 Morgan Stanley
Idorsia price target lowered to CHF 34 from CHF 35 at Morgan Stanley
10/28/20 JPMorgan
Idorsia price target lowered to CHF 30 from CHF 34 at JPMorgan
10/28/20 Deutsche Bank
Idorsia price target lowered to CHF 35 from CHF 38 at Deutsche Bank
NVTA Invitae
$52.55 /

+1.74 (+3.42%)

02/01/21 Oppenheimer
Invitae downgraded to Perform on valuation at Oppenheimer
02/01/21 Oppenheimer
Invitae downgraded to Perform from Outperform at Oppenheimer
11/06/20 Ladenburg
Invitae downgraded to Neutral on valuation at Ladenburg
11/06/20 Ladenburg
Invitae downgraded to Neutral from Buy at Ladenburg
ORPH Orphazyme
$13.07 /

+ (+0.00%)

10/26/20 Guggenheim
Orphazyme initiated with a Buy at Guggenheim
10/26/20 BofA
Orphazyme initiated with a Buy at BofA
10/26/20 BofA
Orphazyme initiated with a Buy at BofA
ORTX Orchard Therapeutics
$8.32 /

+1.055 (+14.52%)

01/07/21 Cantor Fitzgerald
Orchard Therapeutics initiated with an Overweight at Cantor Fitzgerald
01/06/21 Cantor Fitzgerald
Orchard Therapeutics initiated with an Overweight at Cantor Fitzgerald
09/14/20 Oppenheimer
Orchard Therapeutics price target lowered to $16 from $26 at Oppenheimer
09/10/20 SMBC Nikko
Orchard Therapeutics initiated with an Outperform at SMBC Nikko
PASG Passage Bio
$20.12 /

-0.57 (-2.75%)

02/04/21
Fly Intel: Top five analyst initiations
02/04/21 Guggenheim
Passage Bio initiated with a Buy at Guggenheim
01/25/21 Citi
Citi upgrades Passage Bio to Buy after pullback and ahead of data
01/25/21 Citi
Passage Bio upgraded to Buy from Neutral at Citi
PFE Pfizer
$34.96 /

+0.14 (+0.40%)

02/04/21 DZ Bank
Pfizer upgraded to Buy from Hold at DZ Bank
02/03/21 Mizuho
Pfizer price target lowered to $42 from $44 at Mizuho
02/01/21 SVB Leerink
Moderna price target raised to $80 from $69 at SVB Leerink
01/29/21 Piper Sandler
Moderna, Pfizer keep Covid vaccine competitive advantage, says Piper Sandler
RARE Ultragenyx
$167.72 /

+1.9 (+1.15%)

01/25/21 Credit Suisse
Ultragenyx price target raised to $99 from $64 at Credit Suisse
01/11/21 Baird
Ultragenyx price target raised to $165 from $110 at Baird
01/11/21 Barclays
Ultragenyx price target raised to $176 from $121 at Barclays
01/08/21 Piper Sandler
Ultragenyx price target raised to $165 from $108 at Piper Sandler
SGTX Sigilon Therapeutics
$38.27 /

-0.4 (-1.03%)

12/29/20 Barclays
Sigilon Therapeutics initiated with an Overweight at Barclays
12/29/20 Morgan Stanley
Sigilon Therapeutics initiated with an Equal Weight at Morgan Stanley
12/29/20 Jefferies
Sigilon Therapeutics initiated with a Buy at Jefferies
SNY Sanofi
$48.87 /

+0.275 (+0.57%)

02/05/21 Piper Sandler
Piper reiterates Overweight on Kymera after Sanofi capital markets day
01/19/21 UBS
Sanofi price target lowered to EUR 99 from EUR 100 at UBS
01/15/21 Deutsche Bank
Sanofi initiated with a Sell at Deutsche Bank
01/08/21 Morgan Stanley
Sanofi price target raised to EUR 105 from EUR 101 at Morgan Stanley
TAK Takeda Pharmaceutical
$17.73 /

+0.315 (+1.81%)

01/29/21 Morgan Stanley
Morgan Stanley downgrades Jazz to Equal Weight ahead of competitor readout
12/29/20 Needham
Needham names Phathom Pharmaceuticals Top Pick for 2021
12/15/20 Needham
Phathom Pharmaceuticals price target raised to $55 from $45 at Needham
06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
TVTX Travere Therapeutics
$29.91 /

-1.09 (-3.52%)

02/03/21
Travere Therapeutics price target raised to $48 from $33 at BMO Capital
02/03/21 Canaccord
Travere Therapeutics price target raised to $51 from $28 at Canaccord
11/23/20 Evercore ISI
Travere Therapeutics initiated with an Outperform at Evercore ISI
TVTX Travere Therapeutics
$29.91 /

-1.09 (-3.52%)

SNY Sanofi
$48.87 /

+0.275 (+0.57%)

RARE Ultragenyx
$167.72 /

+1.9 (+1.15%)

PFE Pfizer
$34.96 /

+0.14 (+0.40%)

PASG Passage Bio
$20.12 /

-0.57 (-2.75%)

ORTX Orchard Therapeutics
$8.32 /

+1.055 (+14.52%)

NVTA Invitae
$52.55 /

+1.74 (+3.42%)

FOLD Amicus
$19.18 /

-0.7 (-3.52%)

FIXX Homology Medicines
$14.38 /

-0.39 (-2.64%)

DNLI Denali Therapeutics
$72.98 /

-3.57 (-4.66%)

BMRN BioMarin
$85.63 /

-0.55 (-0.64%)

AVRO Avrobio
$17.68 /

-1.62 (-8.39%)

ABEO Abeona Therapeutics
$3.32 /

-0.05 (-1.48%)

  • 22
    Jan
  • 22
    Jan
  • 04
    Dec
  • 20
    Nov
  • 29
    Oct
  • 29
    Sep
  • 02
    Apr
  • 28
    Feb
  • 13
    Feb
TAK Takeda Pharmaceutical
$17.73 /

+0.315 (+1.81%)

SNY Sanofi
$48.87 /

+0.275 (+0.57%)

PFE Pfizer
$34.96 /

+0.14 (+0.40%)

FOLD Amicus
$19.18 /

-0.7 (-3.52%)

BMRN BioMarin
$85.63 /

-0.55 (-0.64%)

TAK Takeda Pharmaceutical
$17.73 /

+0.315 (+1.81%)

SNY Sanofi
$48.87 /

+0.275 (+0.57%)

SGTX Sigilon Therapeutics
$38.27 /

-0.4 (-1.03%)

PFE Pfizer
$34.96 /

+0.14 (+0.40%)

PASG Passage Bio
$20.12 /

-0.57 (-2.75%)

ORPH Orphazyme
$13.07 /

+ (+0.00%)

NVTA Invitae
$52.55 /

+1.74 (+3.42%)

FOLD Amicus
$19.18 /

-0.7 (-3.52%)

DNLI Denali Therapeutics
$72.98 /

-3.57 (-4.66%)

BMRN BioMarin
$85.63 /

-0.55 (-0.64%)

AVRO Avrobio
$17.68 /

-1.62 (-8.39%)

TVTX Travere Therapeutics
$29.91 /

-1.09 (-3.52%)

TAK Takeda Pharmaceutical
$17.73 /

+0.315 (+1.81%)

PFE Pfizer
$34.96 /

+0.14 (+0.40%)

PASG Passage Bio
$20.12 /

-0.57 (-2.75%)

NVTA Invitae
$52.55 /

+1.74 (+3.42%)

FOLD Amicus
$19.18 /

-0.7 (-3.52%)

BMRN BioMarin
$85.63 /

-0.55 (-0.64%)

Conference/Events
Lysosomal Disease Network to hold a virtual symposium » 04:55
02/09/21
02/09
04:55
02/09/21
04:55
ABEO

Abeona Therapeutics

$3.37 /

+0.78 (+30.12%)

, AVRO

Avrobio

$19.30 /

+2.17 (+12.67%)

, BMRN

BioMarin

$86.19 /

+1.18 (+1.39%)

, DNLI

Denali Therapeutics

$76.96 /

+6.45 (+9.15%)

, FIXX

Homology Medicines

$14.76 /

+0.92 (+6.65%)

, FOLD

Amicus

$19.88 /

-0.21 (-1.05%)

, IDRSF

Idorsia

$0.00 /

+ (+0.00%)

, NVTA

Invitae

$50.81 /

+1.19 (+2.40%)

, ORPH

Orphazyme

$13.07 /

+0.57 (+4.56%)

, ORTX

Orchard Therapeutics

$7.27 /

-0.085 (-1.16%)

, PASG

Passage Bio

$20.69 /

-0.86 (-3.99%)

, PFE

Pfizer

$34.82 /

-0.1 (-0.29%)

, RARE

Ultragenyx

$166.04 /

+4.28 (+2.65%)

, SGTX

Sigilon Therapeutics

$38.70 /

+4.52 (+13.22%)

, SNY

Sanofi

$48.60 /

+0.4 (+0.83%)

, TAK

Takeda Pharmaceutical

$17.42 /

+0.235 (+1.37%)

, TVTX

Travere Therapeutics

$31.00 /

-0.55 (-1.74%)

17th Annual Virtual…

17th Annual Virtual WORLDSymposium 2021 will be held on February 8-12. Webcast Link

ShowHide Related Items >><<
TVTX Travere Therapeutics
$31.00 /

-0.55 (-1.74%)

TAK Takeda Pharmaceutical
$17.42 /

+0.235 (+1.37%)

SNY Sanofi
$48.60 /

+0.4 (+0.83%)

SGTX Sigilon Therapeutics
$38.70 /

+4.52 (+13.22%)

RARE Ultragenyx
$166.04 /

+4.28 (+2.65%)

PFE Pfizer
$34.82 /

-0.1 (-0.29%)

PASG Passage Bio
$20.69 /

-0.86 (-3.99%)

ORTX Orchard Therapeutics
$7.27 /

-0.085 (-1.16%)

ORPH Orphazyme
$13.07 /

+0.57 (+4.56%)

NVTA Invitae
$50.81 /

+1.19 (+2.40%)

FOLD Amicus
$19.88 /

-0.21 (-1.05%)

FIXX Homology Medicines
$14.76 /

+0.92 (+6.65%)

DNLI Denali Therapeutics
$76.96 /

+6.45 (+9.15%)

BMRN BioMarin
$86.19 /

+1.18 (+1.39%)

AVRO Avrobio
$19.30 /

+2.17 (+12.67%)

ABEO Abeona Therapeutics
$3.37 /

+0.78 (+30.12%)

ABEO Abeona Therapeutics
$3.37 /

+0.78 (+30.12%)

11/25/20 H.C. Wainwright
Abeona Therapeutics price target lowered to $8 from $11 at H.C. Wainwright
11/11/20 B. Riley Securities
Abeona Therapeutics price target raised to $3 from $2 at B. Riley Securities
11/10/20 Cantor Fitzgerald
Cantor upgrades Abeona to Overweight with shares trading near cash
11/10/20 Cantor Fitzgerald
Abeona Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
AVRO Avrobio
$19.30 /

+2.17 (+12.67%)

11/18/20 Mizuho
Avrobio price target raised to $43 from $35 at Mizuho
11/11/20 Berenberg
Biotechnology companies initiated at Berenberg
11/11/20 Berenberg
Avrobio initiated with a Buy at Berenberg
03/31/20 H.C. Wainwright
Avrobio downgraded to Neutral from Buy at H.C. Wainwright
BMRN BioMarin
$86.19 /

+1.18 (+1.39%)

01/29/21 Jefferies
Carvana, Walmart among 13 additions to Jefferies Franchise Picks list
01/11/21 Baird
BioMarin price target raised to $110 from $100 at Baird
12/21/20 Piper Sandler
BioMarin data today should ease approvability concerns, says Piper Sandler
12/17/20 JPMorgan
BioMarin remains 'highest conviction name' at JPMorgan
DNLI Denali Therapeutics
$76.96 /

+6.45 (+9.15%)

11/11/20 JPMorgan
Denali Therapeutics price target raised to $65 from $45 at JPMorgan
11/11/20 H.C. Wainwright
Denali Therapeutics price target raised to $80 from $65 at H.C. Wainwright
11/10/20 Goldman Sachs
Denali Therapeutics price target raised to $81 from $61 at Goldman Sachs
11/06/20 H.C. Wainwright
Denali Therapeutics price target raised to $65 from $45 at H.C. Wainwright
FIXX Homology Medicines
$14.76 /

+0.92 (+6.65%)

12/14/20 H.C. Wainwright
Homology Medicines transferred with Buy, $30 target at H.C. Wainwright
11/08/20 Oppenheimer
Homology Medicines selloff unjustified in wake of clinical PoC, says Oppenheimer
08/11/20 Oppenheimer
Homology Medicines price target lowered to $27 from $32 at Oppenheimer
08/11/20 H.C. Wainwright
Homology Medicines price target lowered to $30 from $37 at H.C. Wainwright
FOLD Amicus
$19.88 /

-0.21 (-1.05%)

01/22/21 JPMorgan
Amicus remains top idea into 'meaningful catalyst' at JPMorgan
01/04/21 Cowen
Amicus could move 30%-40% on Pompe study data, says Cowen
12/28/20 Cantor Fitzgerald
Amicus assumed with an Overweight at Cantor Fitzgerald
12/14/20 JPMorgan
JPMorgan boosts Amicus target to $29, adds to Analyst Focus List
IDRSF Idorsia
$0.00 /

+ (+0.00%)

02/08/21 JPMorgan
Idorsia price target lowered to CHF 28 from CHF 31 at JPMorgan
10/29/20 Morgan Stanley
Idorsia price target lowered to CHF 34 from CHF 35 at Morgan Stanley
10/28/20 JPMorgan
Idorsia price target lowered to CHF 30 from CHF 34 at JPMorgan
10/28/20 Deutsche Bank
Idorsia price target lowered to CHF 35 from CHF 38 at Deutsche Bank
NVTA Invitae
$50.81 /

+1.19 (+2.40%)

02/01/21 Oppenheimer
Invitae downgraded to Perform on valuation at Oppenheimer
02/01/21 Oppenheimer
Invitae downgraded to Perform from Outperform at Oppenheimer
11/06/20 Ladenburg
Invitae downgraded to Neutral on valuation at Ladenburg
11/06/20 Ladenburg
Invitae downgraded to Neutral from Buy at Ladenburg
ORPH Orphazyme
$13.07 /

+0.57 (+4.56%)

10/26/20 Guggenheim
Orphazyme initiated with a Buy at Guggenheim
10/26/20 BofA
Orphazyme initiated with a Buy at BofA
10/26/20 BofA
Orphazyme initiated with a Buy at BofA
ORTX Orchard Therapeutics
$7.27 /

-0.085 (-1.16%)

01/07/21 Cantor Fitzgerald
Orchard Therapeutics initiated with an Overweight at Cantor Fitzgerald
01/06/21 Cantor Fitzgerald
Orchard Therapeutics initiated with an Overweight at Cantor Fitzgerald
09/14/20 Oppenheimer
Orchard Therapeutics price target lowered to $16 from $26 at Oppenheimer
09/10/20 SMBC Nikko
Orchard Therapeutics initiated with an Outperform at SMBC Nikko
PASG Passage Bio
$20.69 /

-0.86 (-3.99%)

02/04/21
Fly Intel: Top five analyst initiations
02/04/21 Guggenheim
Passage Bio initiated with a Buy at Guggenheim
01/25/21 Citi
Citi upgrades Passage Bio to Buy after pullback and ahead of data
01/25/21 Citi
Passage Bio upgraded to Buy from Neutral at Citi
PFE Pfizer
$34.82 /

-0.1 (-0.29%)

02/04/21 DZ Bank
Pfizer upgraded to Buy from Hold at DZ Bank
02/03/21 Mizuho
Pfizer price target lowered to $42 from $44 at Mizuho
02/01/21 SVB Leerink
Moderna price target raised to $80 from $69 at SVB Leerink
01/29/21 Piper Sandler
Moderna, Pfizer keep Covid vaccine competitive advantage, says Piper Sandler
RARE Ultragenyx
$166.04 /

+4.28 (+2.65%)

01/25/21 Credit Suisse
Ultragenyx price target raised to $99 from $64 at Credit Suisse
01/11/21 Baird
Ultragenyx price target raised to $165 from $110 at Baird
01/11/21 Barclays
Ultragenyx price target raised to $176 from $121 at Barclays
01/08/21 Piper Sandler
Ultragenyx price target raised to $165 from $108 at Piper Sandler
SGTX Sigilon Therapeutics
$38.70 /

+4.52 (+13.22%)

12/29/20 Barclays
Sigilon Therapeutics initiated with an Overweight at Barclays
12/29/20 Morgan Stanley
Sigilon Therapeutics initiated with an Equal Weight at Morgan Stanley
12/29/20 Jefferies
Sigilon Therapeutics initiated with a Buy at Jefferies
SNY Sanofi
$48.60 /

+0.4 (+0.83%)

02/05/21 Piper Sandler
Piper reiterates Overweight on Kymera after Sanofi capital markets day
01/19/21 UBS
Sanofi price target lowered to EUR 99 from EUR 100 at UBS
01/15/21 Deutsche Bank
Sanofi initiated with a Sell at Deutsche Bank
01/08/21 Morgan Stanley
Sanofi price target raised to EUR 105 from EUR 101 at Morgan Stanley
TAK Takeda Pharmaceutical
$17.42 /

+0.235 (+1.37%)

01/29/21 Morgan Stanley
Morgan Stanley downgrades Jazz to Equal Weight ahead of competitor readout
12/29/20 Needham
Needham names Phathom Pharmaceuticals Top Pick for 2021
12/15/20 Needham
Phathom Pharmaceuticals price target raised to $55 from $45 at Needham
06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
TVTX Travere Therapeutics
$31.00 /

-0.55 (-1.74%)

02/03/21
Travere Therapeutics price target raised to $48 from $33 at BMO Capital
02/03/21 Canaccord
Travere Therapeutics price target raised to $51 from $28 at Canaccord
11/23/20 Evercore ISI
Travere Therapeutics initiated with an Outperform at Evercore ISI
TVTX Travere Therapeutics
$31.00 /

-0.55 (-1.74%)

SNY Sanofi
$48.60 /

+0.4 (+0.83%)

RARE Ultragenyx
$166.04 /

+4.28 (+2.65%)

PFE Pfizer
$34.82 /

-0.1 (-0.29%)

PASG Passage Bio
$20.69 /

-0.86 (-3.99%)

ORTX Orchard Therapeutics
$7.27 /

-0.085 (-1.16%)

NVTA Invitae
$50.81 /

+1.19 (+2.40%)

FOLD Amicus
$19.88 /

-0.21 (-1.05%)

FIXX Homology Medicines
$14.76 /

+0.92 (+6.65%)

DNLI Denali Therapeutics
$76.96 /

+6.45 (+9.15%)

BMRN BioMarin
$86.19 /

+1.18 (+1.39%)

AVRO Avrobio
$19.30 /

+2.17 (+12.67%)

ABEO Abeona Therapeutics
$3.37 /

+0.78 (+30.12%)

  • 22
    Jan
  • 22
    Jan
  • 04
    Dec
  • 20
    Nov
  • 29
    Oct
  • 29
    Sep
  • 02
    Apr
  • 28
    Feb
  • 13
    Feb
TAK Takeda Pharmaceutical
$17.42 /

+0.235 (+1.37%)

SNY Sanofi
$48.60 /

+0.4 (+0.83%)

PFE Pfizer
$34.82 /

-0.1 (-0.29%)

FOLD Amicus
$19.88 /

-0.21 (-1.05%)

BMRN BioMarin
$86.19 /

+1.18 (+1.39%)

TAK Takeda Pharmaceutical
$17.42 /

+0.235 (+1.37%)

SNY Sanofi
$48.60 /

+0.4 (+0.83%)

SGTX Sigilon Therapeutics
$38.70 /

+4.52 (+13.22%)

PFE Pfizer
$34.82 /

-0.1 (-0.29%)

PASG Passage Bio
$20.69 /

-0.86 (-3.99%)

ORPH Orphazyme
$13.07 /

+0.57 (+4.56%)

NVTA Invitae
$50.81 /

+1.19 (+2.40%)

FOLD Amicus
$19.88 /

-0.21 (-1.05%)

DNLI Denali Therapeutics
$76.96 /

+6.45 (+9.15%)

BMRN BioMarin
$86.19 /

+1.18 (+1.39%)

AVRO Avrobio
$19.30 /

+2.17 (+12.67%)

TVTX Travere Therapeutics
$31.00 /

-0.55 (-1.74%)

TAK Takeda Pharmaceutical
$17.42 /

+0.235 (+1.37%)

PFE Pfizer
$34.82 /

-0.1 (-0.29%)

PASG Passage Bio
$20.69 /

-0.86 (-3.99%)

NVTA Invitae
$50.81 /

+1.19 (+2.40%)

FOLD Amicus
$19.88 /

-0.21 (-1.05%)

BMRN BioMarin
$86.19 /

+1.18 (+1.39%)

Conference/Events
Lysosomal Disease Network to hold a virtual symposium » 08:57
02/08/21
02/08
08:57
02/08/21
08:57
ABEO

Abeona Therapeutics

$2.59 /

+0.13 (+5.28%)

, AVRO

Avrobio

$17.13 /

+1.11 (+6.93%)

, BMRN

BioMarin

$85.26 /

+0.62 (+0.73%)

, DNLI

Denali Therapeutics

$70.51 /

+0.92 (+1.32%)

, FIXX

Homology Medicines

$13.83 /

+0.45 (+3.36%)

, FOLD

Amicus

$20.09 /

-0.09 (-0.45%)

, IDRSF

Idorsia

$0.00 /

+ (+0.00%)

, NVTA

Invitae

$49.65 /

-0.495 (-0.99%)

, ORPH

Orphazyme

$12.50 /

+0.39 (+3.22%)

, ORTX

Orchard Therapeutics

$7.35 /

+1.155 (+18.64%)

, PASG

Passage Bio

$21.49 /

-0.41 (-1.87%)

, PFE

Pfizer

$34.92 /

+0.03 (+0.09%)

, RARE

Ultragenyx

$161.76 /

+7.21 (+4.67%)

, SGTX

Sigilon Therapeutics

$34.25 /

-0.35 (-1.01%)

, SNY

Sanofi

$48.19 /

+1.11 (+2.36%)

, TAK

Takeda Pharmaceutical

$17.19 /

-0.005 (-0.03%)

, TVTX

Travere Therapeutics

$31.81 /

+0.29 (+0.92%)

17th Annual Virtual…

17th Annual Virtual WORLDSymposium 2021 will be held on February 8-12. Webcast Link

ShowHide Related Items >><<
TVTX Travere Therapeutics
$31.81 /

+0.29 (+0.92%)

TAK Takeda Pharmaceutical
$17.19 /

-0.005 (-0.03%)

SNY Sanofi
$48.19 /

+1.11 (+2.36%)

SGTX Sigilon Therapeutics
$34.25 /

-0.35 (-1.01%)

RARE Ultragenyx
$161.76 /

+7.21 (+4.67%)

PFE Pfizer
$34.92 /

+0.03 (+0.09%)

PASG Passage Bio
$21.49 /

-0.41 (-1.87%)

ORTX Orchard Therapeutics
$7.35 /

+1.155 (+18.64%)

ORPH Orphazyme
$12.50 /

+0.39 (+3.22%)

NVTA Invitae
$49.65 /

-0.495 (-0.99%)

FOLD Amicus
$20.09 /

-0.09 (-0.45%)

FIXX Homology Medicines
$13.83 /

+0.45 (+3.36%)

DNLI Denali Therapeutics
$70.51 /

+0.92 (+1.32%)

BMRN BioMarin
$85.26 /

+0.62 (+0.73%)

AVRO Avrobio
$17.13 /

+1.11 (+6.93%)

ABEO Abeona Therapeutics
$2.59 /

+0.13 (+5.28%)

ABEO Abeona Therapeutics
$2.59 /

+0.13 (+5.28%)

11/25/20 H.C. Wainwright
Abeona Therapeutics price target lowered to $8 from $11 at H.C. Wainwright
11/11/20 B. Riley Securities
Abeona Therapeutics price target raised to $3 from $2 at B. Riley Securities
11/10/20 Cantor Fitzgerald
Cantor upgrades Abeona to Overweight with shares trading near cash
11/10/20 Cantor Fitzgerald
Abeona Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald
AVRO Avrobio
$17.13 /

+1.11 (+6.93%)

11/18/20 Mizuho
Avrobio price target raised to $43 from $35 at Mizuho
11/11/20 Berenberg
Biotechnology companies initiated at Berenberg
11/11/20 Berenberg
Avrobio initiated with a Buy at Berenberg
03/31/20 H.C. Wainwright
Avrobio downgraded to Neutral from Buy at H.C. Wainwright
BMRN BioMarin
$85.26 /

+0.62 (+0.73%)

01/29/21 Jefferies
Carvana, Walmart among 13 additions to Jefferies Franchise Picks list
01/11/21 Baird
BioMarin price target raised to $110 from $100 at Baird
12/21/20 Piper Sandler
BioMarin data today should ease approvability concerns, says Piper Sandler
12/17/20 JPMorgan
BioMarin remains 'highest conviction name' at JPMorgan
DNLI Denali Therapeutics
$70.51 /

+0.92 (+1.32%)

11/11/20 JPMorgan
Denali Therapeutics price target raised to $65 from $45 at JPMorgan
11/11/20 H.C. Wainwright
Denali Therapeutics price target raised to $80 from $65 at H.C. Wainwright
11/10/20 Goldman Sachs
Denali Therapeutics price target raised to $81 from $61 at Goldman Sachs
11/06/20 H.C. Wainwright
Denali Therapeutics price target raised to $65 from $45 at H.C. Wainwright
FIXX Homology Medicines
$13.83 /

+0.45 (+3.36%)

12/14/20 H.C. Wainwright
Homology Medicines transferred with Buy, $30 target at H.C. Wainwright
11/08/20 Oppenheimer
Homology Medicines selloff unjustified in wake of clinical PoC, says Oppenheimer
08/11/20 Oppenheimer
Homology Medicines price target lowered to $27 from $32 at Oppenheimer
08/11/20 H.C. Wainwright
Homology Medicines price target lowered to $30 from $37 at H.C. Wainwright
FOLD Amicus
$20.09 /

-0.09 (-0.45%)

01/22/21 JPMorgan
Amicus remains top idea into 'meaningful catalyst' at JPMorgan
01/04/21 Cowen
Amicus could move 30%-40% on Pompe study data, says Cowen
12/28/20 Cantor Fitzgerald
Amicus assumed with an Overweight at Cantor Fitzgerald
12/14/20 JPMorgan
JPMorgan boosts Amicus target to $29, adds to Analyst Focus List
IDRSF Idorsia
$0.00 /

+ (+0.00%)

10/29/20 Morgan Stanley
Idorsia price target lowered to CHF 34 from CHF 35 at Morgan Stanley
10/28/20 JPMorgan
Idorsia price target lowered to CHF 30 from CHF 34 at JPMorgan
10/28/20 Deutsche Bank
Idorsia price target lowered to CHF 35 from CHF 38 at Deutsche Bank
07/27/20 Morgan Stanley
Idorsia initiated with an Equal Weight at Morgan Stanley
NVTA Invitae
$49.65 /

-0.495 (-0.99%)

02/01/21 Oppenheimer
Invitae downgraded to Perform on valuation at Oppenheimer
02/01/21 Oppenheimer
Invitae downgraded to Perform from Outperform at Oppenheimer
11/06/20 Ladenburg
Invitae downgraded to Neutral on valuation at Ladenburg
11/06/20 Ladenburg
Invitae downgraded to Neutral from Buy at Ladenburg
ORPH Orphazyme
$12.50 /

+0.39 (+3.22%)

10/26/20 Guggenheim
Orphazyme initiated with a Buy at Guggenheim
10/26/20 BofA
Orphazyme initiated with a Buy at BofA
10/26/20 BofA
Orphazyme initiated with a Buy at BofA
ORTX Orchard Therapeutics
$7.35 /

+1.155 (+18.64%)

01/07/21 Cantor Fitzgerald
Orchard Therapeutics initiated with an Overweight at Cantor Fitzgerald
01/06/21 Cantor Fitzgerald
Orchard Therapeutics initiated with an Overweight at Cantor Fitzgerald
09/14/20 Oppenheimer
Orchard Therapeutics price target lowered to $16 from $26 at Oppenheimer
09/10/20 SMBC Nikko
Orchard Therapeutics initiated with an Outperform at SMBC Nikko
PASG Passage Bio
$21.49 /

-0.41 (-1.87%)

02/04/21
Fly Intel: Top five analyst initiations
02/04/21 Guggenheim
Passage Bio initiated with a Buy at Guggenheim
01/25/21 Citi
Citi upgrades Passage Bio to Buy after pullback and ahead of data
01/25/21 Citi
Passage Bio upgraded to Buy from Neutral at Citi
PFE Pfizer
$34.92 /

+0.03 (+0.09%)

02/04/21 DZ Bank
Pfizer upgraded to Buy from Hold at DZ Bank
02/03/21 Mizuho
Pfizer price target lowered to $42 from $44 at Mizuho
02/01/21 SVB Leerink
Moderna price target raised to $80 from $69 at SVB Leerink
01/29/21 Piper Sandler
Moderna, Pfizer keep Covid vaccine competitive advantage, says Piper Sandler
RARE Ultragenyx
$161.76 /

+7.21 (+4.67%)

01/25/21 Credit Suisse
Ultragenyx price target raised to $99 from $64 at Credit Suisse
01/11/21 Baird
Ultragenyx price target raised to $165 from $110 at Baird
01/11/21 Barclays
Ultragenyx price target raised to $176 from $121 at Barclays
01/08/21 Piper Sandler
Ultragenyx price target raised to $165 from $108 at Piper Sandler
SGTX Sigilon Therapeutics
$34.25 /

-0.35 (-1.01%)

12/29/20 Barclays
Sigilon Therapeutics initiated with an Overweight at Barclays
12/29/20 Morgan Stanley
Sigilon Therapeutics initiated with an Equal Weight at Morgan Stanley
12/29/20 Jefferies
Sigilon Therapeutics initiated with a Buy at Jefferies
SNY Sanofi
$48.19 /

+1.11 (+2.36%)

02/05/21 Piper Sandler
Piper reiterates Overweight on Kymera after Sanofi capital markets day
01/19/21 UBS
Sanofi price target lowered to EUR 99 from EUR 100 at UBS
01/15/21 Deutsche Bank
Sanofi initiated with a Sell at Deutsche Bank
01/08/21 Morgan Stanley
Sanofi price target raised to EUR 105 from EUR 101 at Morgan Stanley
TAK Takeda Pharmaceutical
$17.19 /

-0.005 (-0.03%)

01/29/21 Morgan Stanley
Morgan Stanley downgrades Jazz to Equal Weight ahead of competitor readout
12/29/20 Needham
Needham names Phathom Pharmaceuticals Top Pick for 2021
12/15/20 Needham
Phathom Pharmaceuticals price target raised to $55 from $45 at Needham
06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
TVTX Travere Therapeutics
$31.81 /

+0.29 (+0.92%)

02/03/21
Travere Therapeutics price target raised to $48 from $33 at BMO Capital
02/03/21 Canaccord
Travere Therapeutics price target raised to $51 from $28 at Canaccord
11/23/20 Evercore ISI
Travere Therapeutics initiated with an Outperform at Evercore ISI
TVTX Travere Therapeutics
$31.81 /

+0.29 (+0.92%)

SNY Sanofi
$48.19 /

+1.11 (+2.36%)

RARE Ultragenyx
$161.76 /

+7.21 (+4.67%)

PFE Pfizer
$34.92 /

+0.03 (+0.09%)

PASG Passage Bio
$21.49 /

-0.41 (-1.87%)

ORTX Orchard Therapeutics
$7.35 /

+1.155 (+18.64%)

NVTA Invitae
$49.65 /

-0.495 (-0.99%)

FOLD Amicus
$20.09 /

-0.09 (-0.45%)

FIXX Homology Medicines
$13.83 /

+0.45 (+3.36%)

DNLI Denali Therapeutics
$70.51 /

+0.92 (+1.32%)

BMRN BioMarin
$85.26 /

+0.62 (+0.73%)

AVRO Avrobio
$17.13 /

+1.11 (+6.93%)

ABEO Abeona Therapeutics
$2.59 /

+0.13 (+5.28%)

  • 22
    Jan
  • 22
    Jan
  • 04
    Dec
  • 20
    Nov
  • 29
    Oct
  • 29
    Sep
  • 02
    Apr
  • 28
    Feb
  • 13
    Feb
TAK Takeda Pharmaceutical
$17.19 /

-0.005 (-0.03%)

SNY Sanofi
$48.19 /

+1.11 (+2.36%)

PFE Pfizer
$34.92 /

+0.03 (+0.09%)

FOLD Amicus
$20.09 /

-0.09 (-0.45%)

BMRN BioMarin
$85.26 /

+0.62 (+0.73%)

TAK Takeda Pharmaceutical
$17.19 /

-0.005 (-0.03%)

SNY Sanofi
$48.19 /

+1.11 (+2.36%)

SGTX Sigilon Therapeutics
$34.25 /

-0.35 (-1.01%)

PFE Pfizer
$34.92 /

+0.03 (+0.09%)

PASG Passage Bio
$21.49 /

-0.41 (-1.87%)

ORPH Orphazyme
$12.50 /

+0.39 (+3.22%)

NVTA Invitae
$49.65 /

-0.495 (-0.99%)

FOLD Amicus
$20.09 /

-0.09 (-0.45%)

DNLI Denali Therapeutics
$70.51 /

+0.92 (+1.32%)

BMRN BioMarin
$85.26 /

+0.62 (+0.73%)

AVRO Avrobio
$17.13 /

+1.11 (+6.93%)

TVTX Travere Therapeutics
$31.81 /

+0.29 (+0.92%)

TAK Takeda Pharmaceutical
$17.19 /

-0.005 (-0.03%)

PFE Pfizer
$34.92 /

+0.03 (+0.09%)

PASG Passage Bio
$21.49 /

-0.41 (-1.87%)

NVTA Invitae
$49.65 /

-0.495 (-0.99%)

FOLD Amicus
$20.09 /

-0.09 (-0.45%)

BMRN BioMarin
$85.26 /

+0.62 (+0.73%)

Conference/Events
European Association for Hemophilia & Allied Disorders to hold conference » 04:55
02/05/21
02/05
04:55
02/05/21
04:55
BAYRY

Bayer

$0.00 /

+ (+0.00%)

, BMRN

BioMarin

$84.69 /

+1.72 (+2.07%)

, NVO

Novo Nordisk

$71.66 /

-0.78 (-1.08%)

, PFE

Pfizer

$34.88 /

+0.04 (+0.11%)

, SNY

Sanofi

$47.09 /

+0.23 (+0.49%)

, TAK

Takeda Pharmaceutical

$17.19 /

-0.235 (-1.35%)

EAHAD 2021 Virtual…

EAHAD 2021 Virtual Congress will be held on February 2-5. Webcast Link

ShowHide Related Items >><<
TAK Takeda Pharmaceutical
$17.19 /

-0.235 (-1.35%)

SNY Sanofi
$47.09 /

+0.23 (+0.49%)

PFE Pfizer
$34.88 /

+0.04 (+0.11%)

NVO Novo Nordisk
$71.66 /

-0.78 (-1.08%)

BMRN BioMarin
$84.69 /

+1.72 (+2.07%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

02/04/21
Citi opens positive 'Catalyst Watch' on Bayer
01/27/21 Deutsche Bank
Bayer price target raised to EUR 63 from EUR 62 at Deutsche Bank
01/20/21 Credit Suisse
Bayer price target raised to EUR 55 from EUR 47 at Credit Suisse
01/08/21 Morgan Stanley
Bayer price target lowered to EUR 66 from EUR 67 at Morgan Stanley
BMRN BioMarin
$84.69 /

+1.72 (+2.07%)

01/29/21 Jefferies
Carvana, Walmart among 13 additions to Jefferies Franchise Picks list
01/11/21 Baird
BioMarin price target raised to $110 from $100 at Baird
12/21/20 Piper Sandler
BioMarin data today should ease approvability concerns, says Piper Sandler
12/17/20 JPMorgan
BioMarin remains 'highest conviction name' at JPMorgan
NVO Novo Nordisk
$71.66 /

-0.78 (-1.08%)

02/04/21 Barclays
Novo Nordisk price target raised to DKK 495 from DKK 485 at Barclays
01/20/21 Citi
Citi opens 'Positive Catalyst Watch' on Novo Nordisk
01/20/21 Credit Suisse
Novo Nordisk downgraded to Neutral from Outperform at Credit Suisse
01/20/21 Credit Suisse
Novo Nordisk downgraded to Neutral from Outperform at Credit Suisse
PFE Pfizer
$34.88 /

+0.04 (+0.11%)

02/04/21 DZ Bank
Pfizer upgraded to Buy from Hold at DZ Bank
02/03/21 Mizuho
Pfizer price target lowered to $42 from $44 at Mizuho
02/01/21 SVB Leerink
Moderna price target raised to $80 from $69 at SVB Leerink
01/29/21 Piper Sandler
Moderna, Pfizer keep Covid vaccine competitive advantage, says Piper Sandler
SNY Sanofi
$47.09 /

+0.23 (+0.49%)

01/19/21 UBS
Sanofi price target lowered to EUR 99 from EUR 100 at UBS
01/15/21 Deutsche Bank
Sanofi initiated with a Sell at Deutsche Bank
01/08/21 Morgan Stanley
Sanofi price target raised to EUR 105 from EUR 101 at Morgan Stanley
01/08/21 Morgan Stanley
Roche downgraded to Equal Weight from Overweight at Morgan Stanley
TAK Takeda Pharmaceutical
$17.19 /

-0.235 (-1.35%)

01/29/21 Morgan Stanley
Morgan Stanley downgrades Jazz to Equal Weight ahead of competitor readout
12/29/20 Needham
Needham names Phathom Pharmaceuticals Top Pick for 2021
12/15/20 Needham
Phathom Pharmaceuticals price target raised to $55 from $45 at Needham
06/18/20 RBC Capital
Neurocrine price target raised to $135 from $116 at RBC Capital
SNY Sanofi
$47.09 /

+0.23 (+0.49%)

PFE Pfizer
$34.88 /

+0.04 (+0.11%)

NVO Novo Nordisk
$71.66 /

-0.78 (-1.08%)

BMRN BioMarin
$84.69 /

+1.72 (+2.07%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

TAK Takeda Pharmaceutical
$17.19 /

-0.235 (-1.35%)

SNY Sanofi
$47.09 /

+0.23 (+0.49%)

PFE Pfizer
$34.88 /

+0.04 (+0.11%)

BMRN BioMarin
$84.69 /

+1.72 (+2.07%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

TAK Takeda Pharmaceutical
$17.19 /

-0.235 (-1.35%)

SNY Sanofi
$47.09 /

+0.23 (+0.49%)

PFE Pfizer
$34.88 /

+0.04 (+0.11%)

NVO Novo Nordisk
$71.66 /

-0.78 (-1.08%)

BMRN BioMarin
$84.69 /

+1.72 (+2.07%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

TAK Takeda Pharmaceutical
$17.19 /

-0.235 (-1.35%)

PFE Pfizer
$34.88 /

+0.04 (+0.11%)

NVO Novo Nordisk
$71.66 /

-0.78 (-1.08%)

BMRN BioMarin
$84.69 /

+1.72 (+2.07%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.